Global Primary Clostridioides Difficile Infection Market – Industry Trends and Forecast to 2029

Primary Clostridioides Difficile Infection Market Analysis and Size

The global primary clostridioides difficile infection market is expected to witness significant growth during the forecast period.  Clostridium difficile infection has significantly increased in recent years as many new strains have appeared and antimicrobial resistance has increased. It is one of the closely associated causes of antibiotic-related diarrhea, with symptoms such as pseudomembranous colitis, mild, self-limiting diarrhea to severe diarrhea, and life-threatening fulminant colitis, which typically results in death. COVID-19 also had a major impact on the market growth.

 Data Bridge Market Research analyses a growth rate in the global primary clostridioides difficile infection market in the forecast period 2022-2029. The expected CAGR of global primary clostridioides difficile infection market is tend to be around 6.30% in the mentioned forecast period. The market was valued at USD 1 billion in 2021, and it would grow upto USD 1.63 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Primary clostridioides difficile is a bacterial infection that can cause symptoms ranging from diarrhea to life-threatening colon inflammation. It has also evolved as a cause of community-associated diarrhea, ensuing in an increased prevalence of community-associated infection. Clinical illness ranges in severity from mild diarrhea to fulminant colitis and death.

Primary Clostridioides Difficile Infection Market Scope and Segmentation

Global Primary Clostridioides Difficile Infection Market Dynamics

Drivers

• Rising Adoption of Antibiotics

Clostridium difficile infection is primarily associated with long-term antibiotic use. Increased antibiotic consumption changes the colon bacteria, allowing Clostridium difficile bacteria to grow. Antibiotics such as cephalosporins, clindamycin, and quinolones are more likely to cause Clostridium difficile infection (CDI). The higher use of these antibiotics is increasing the prevalence of clostridium difficile infection, which is most likely to boost the demand for its treatments. Therefore, the increasing consumption of antibiotics acts as a major driver of growth in the global primary clostridium difficile infection treatment market.

• Growing Collaborations of Public-Private Organizations

With numerous small innovative players who are functioning in the market, there are several high-growth opportunities for major stakeholders to buy out companies so as to understand microbiomes with the aim of identifying new drugs and drug targets for multiple indications, such as liver disorders, diabetes, obesity, and metabolic disorders. Many market players are focusing on strategic collaborations and partnerships to increase their product pipelines with well-organized R&D techniques. Major companies have had numerous collaborations and partnerships in the last two years. Thus, all these partnerships are boosting the growth of the market.

Opportunities

• Rising Drug Development Activities

Higher drug development activities for developing and launching several new drugs are projected to create market opportunities for growth in the market by providing doctors with an alternate treatment option. Additionally, the development of a new class of non-antibiotic drugs and vaccines is most likely to open up a large number of opportunities for major market players while also increasing the competition for manufacturing better treatment options. Therefore, increased drug development activities for developing novel drugs for better treatment and prevention are anticipated to create market growth in the near future.

• Increasing Demand for Retail Pharmacies

The rise in the number of these infections therapeutics being delivered through retail pharmacies and the surge in the number of retail pharmacies in highly developed countries create much opportunities for the market growth. In addition, patients elect retail pharmacies to purchase drugs, as these are easily feasible.

 Restraints/Challenges

• Lack of skilled professionals

The lack of trained who cannot treat the patients with appropriate treatments could limit the growth of the global primary clostridioides difficile infection market during a forecast period.

• High Cost For Drug Development

The current treatment options that are available for CDIs are limited to antibiotics, and numerous pharmaceutical companies are presently focusing on developing non-antibiotic alternatives. The development of a new class of drugs will offer many growth opportunities for key players, but it will also essentially require major investments in R&D activities of novel therapies. The significantly high investment requirements may act as an obstacle to market growth.  

This global primary clostridioides difficile infection market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global primary clostridioides difficile infection market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Primary Clostridioides Difficile Infection Market       

COVID-19 has largely impacted and could continue to impact other companies' businesses, including their preclinical trials and clinical trials of microbiome-based therapeutics and diagnostic products. Although, with the relaxation of government restrictions associated with the pandemic and the occurrence of virtual clinical trials, R&D activities started their recovery since 2021.

Still, in the post-pandemic era, the biotechnology and pharmaceutical industries are expected to witness a huge growth in the future, as research and treatments are drifting towards normal patients again. Thus, this will significantly impact the global primary clostridioides difficile infection market.

Global Primary Clostridioides Difficile Infection Market Scope

The global primary clostridioides difficile infection market is segmented on the basis of treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Medication
• Surgery
• Others

Route of Administration

• Oral
• Injectable
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Primary Clostridioides Difficile Infection Market Regional Analysis/Insights

The global primary clostridioides difficile infection market is analysed and market size insights and trends are provided by treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global primary clostridioides difficile infection market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for global primary clostridioides difficile infection market throughout the forecasted period due to the presence of key manufacture of the product and increased prevalence of clostridioides difficile infection in this region.  

Asia-Pacific dominates the market due to increased prevalence of clostridioides difficile infection and increasing population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Primary Clostridioides Difficile Infection Market Share Analysis

The global primary clostridioides difficile infection market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global primary clostridioides difficile infection market.

Key players operating in the global primary clostridioides difficile infection market include:

• AstraZeneca (U.K.)
• Lilly (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Novartis AG (Switzerland)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Merck & Co., Inc. (U.S.)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Hikma Pharmaceuticals PLC (U.K.)
• Cipla Inc. (India)
• STI Pharma, LLC (U.S.)

SKU-54393